Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Antibody drug conjugate shows early promise in small cell lung cancer

Share :

2016 ASCO Annual Meeting

3 - 7 Jun 2016
Published: 5 Jun 2016
Views: 2183
Rating:
Save
Dr Charles Rudin - Memorial Sloan Kettering Cancer Center, New York, USA

Dr Rudin presents at ASCO 2016, early findings from a first-in-human clinical trial which showed that antibody drug conjugate (ADC) rovalpituzumab tesirine (Rova-T) demonstrated promising efficacy against recurrent small cell lung cancer (SCLC).

Read the news story for more.

Related Videos

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale...
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus ( Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale Tomasini )
25 Mar 2024
Updates on lung cancer from WCLC and ESMO 2023
Dr Luis Raez - Memorial Cancer Institute, Miami, USA
Updates on lung cancer from WCLC and ESMO 2023 ( Dr Luis Raez - Memorial Cancer Institute, Miami, USA )
31 Jan 2024
Adagrasib shows durable clinical benefit in advanced KRAS-mutant NSCLC
Dr Shirish Gadgeel - Henry Ford Cancer Institute, Detroit, USA
Adagrasib shows durable clinical benefit in advanced KRAS-mutant NSCLC ( Dr Shirish Gadgeel - Henry Ford Cancer Institute, Detroit, USA )
17 Oct 2023
OncoAlert round up July 28th to August 3rd, 2023
Dr Gil Morgan - Executive Director, OncoAlert
OncoAlert round up July 28th to August 3rd, 2023 ( Dr Gil Morgan - Executive Director, OncoAlert )
4 Aug 2023
Tusamitamab ravtansine combined with SoC shows encouraging anti-tumour activity...
Dr Luis Paz-Ares - Hospital Universitario 12 de Octubre, Madrid, Spain
Tusamitamab ravtansine combined with SoC shows encouraging anti-tumour activity for patients with nonsquamous NSCLC ( Dr Luis Paz-Ares - Hospital Universitario 12 de Octubre, Madrid, Spain )
26 Apr 2023
Four chemo cycles given with durvalumab and tremelimumab optimise response and...
Dr Niels Reinmuth - University of Muenster, Gauting, Germany
Four chemo cycles given with durvalumab and tremelimumab optimise response and tumour shrinkage in patients with mNSCLC ( Dr Niels Reinmuth - University of Muenster, Gauting, Germany )
6 Apr 2023
LUMINANCE: Results support use of durvalumab and platinum-etoposide for...
Dr Niels Reinmuth - University of Muenster, Gauting, Germany
LUMINANCE: Results support use of durvalumab and platinum-etoposide for extensive stage SCLC ( Dr Niels Reinmuth - University of Muenster, Gauting, Germany )
6 Apr 2023
OncoAlert and ecancer weekly round up for August 8th - 14th, 2022
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
OncoAlert and ecancer weekly round up for August 8th - 14th, 2022 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )
15 Aug 2022
ASCO Direct Highlights 2022: lung cancer highlights
Dr Tom Stinchcombe - Duke Cancer Center, Durham, USA
ASCO Direct Highlights 2022: lung cancer highlights ( Dr Tom Stinchcombe - Duke Cancer Center, Durham, USA )
9 Jul 2022

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation